RESVEGA, a Nutraceutical Omega-3/Resveratrol Supplementation, Reduces Angiogenesis in a Preclinical Mouse Model of Choroidal Neovascularization.

Fiche publication

Date publication

octobre 2021

Journal

International journal of molecular sciences

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DELMAS Dominique , Dr PAIS DE BARROS Jean-Paul , Dr AIRES Virginie

Tous les auteurs :
Courtaut F, Aires V, Acar N, Bretillon L, Guerrera IC, Chhuon C, Pais de Barros JP, Olmiere C, Delmas D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34681683

Résumé

Age-related macular degeneration (AMD) is an eye disease that is characterized by damage to the central part of the retina, the macula, and that affects millions of people worldwide. At an advanced stage, a blind spot grows in the center of vision, severely handicapping patients with this degenerative condition. Despite therapeutic advances thanks to the use of anti-VEGF, many resistance mechanisms have been found to accentuate the visual deficit. In the present study, we explored whether supplementation with Resvega, a nutraceutical formulation composed of omega-3 fatty acids and resveratrol, a well-known polyphenol in grapes, was able to counteract laser-induced choroidal neovascularization (CNV) in mice. We highlight that Resvega significantly reduced CNV in mice compared with supplementations containing omega-3 or resveratrol alone. Moreover, a proteomic approach confirmed that Resvega could counteract the progression of AMD through a pleiotropic effect targeting key regulators of neoangiogenesis in retina cells in vivo. These events were associated with an accumulation of resveratrol metabolites within the retina. Therefore, a supplementation of omega-3/resveratrol could improve the management or slow the progression of AMD in patients with this condition.